One-Year Outcomes of Aflibercept in Treat-and-Extend Versus Pro Re Nata Regimens for Bevacizumab-Resistant Diabetic Macular Edema: A Real-World Study
Yazarlar (3)
Doç. Dr. Zübeyir YOZGAT Kastamonu Üniversitesi, Türkiye
Mehmed Uğur Işık
Kastamonu Üniversitesi, Türkiye
Mehmet Cem Sabaner
Kastamonu Üniversitesi, Türkiye
Makale Türü Açık Erişim Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
Dergi Adı Ophthalmology and Therapy (Q1)
Dergi ISSN 2193-8245 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI-Expanded
Makale Dili İngilizce Basım Tarihi 01-2025
Cilt / Sayı / Sayfa 14 / 1 / 169–181 DOI 10.1007/s40123-024-01067-x
Makale Linki https://doi.org/10.1007/s40123-024-01067-x
UAK Araştırma Alanları
Göz Hastalıkları
Özet
IntroductionThe aim of this study was to compare the efficacy of the treat-and-extend (TAE) regimen versus the pro re nata (PRN) regimen in patients with bevacizumab-resistant diabetic macular edema (DME) treated with aflibercept, with or without adjunctive laser therapy.MethodsNinety-one eyes from 91 patients who were switched to aflibercept after three consecutive intravitreal bevacizumab injections for the treatment of DME were included in this retrospective real-world study. The patients were categorized into three groups: TAE (n = 30), TAE + laser (n = 31), and PRN (n = 30). Changes in best-corrected visual acuity and central macular subfield thickness (CMST) at 12, 24, and 52 weeks were defined as the primary functional and anatomical outcomes.ResultsA total of 91 eyes from 91 patients (49.5% female) with a mean age of 63.9 ± 7.1 years were included in the analysis. At 52 weeks, the mean …
Anahtar Kelimeler
Aflibercept | Bevacizumab-resistant | Diabetic macular edema | Pro re nata regimen | Real-world study | Treat-and-extend regimen
BM Sürdürülebilir Kalkınma Amaçları
Atıf Sayıları
Web of Science 1
Scopus 2
Google Scholar 1
One-Year Outcomes of Aflibercept in Treat-and-Extend Versus Pro Re Nata Regimens for Bevacizumab-Resistant Diabetic Macular Edema: A Real-World Study

Paylaş